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The role of Epstein-Barr virus (EBV) early antigen diffuse component (EA-D) and its relationship with EBV
DNA polymerase in EBV genome-carrying cells are unclear. EBV-specified DNA polymerase was purified in a
sequential manner from Raji cells treated with phorbol-12,13-dibutyrate and n-butyrate by phosphocellulose,
DEAE-cellulose, double-stranded DNA-cellulose, and blue Sepharose column chromatography. Four polypep-
tides with molecular masses of 110,000, 100,000, 55,000, and 49,000 daltons were found to be associated with
EBV-specified DNA polymerase activity. A monoclonal antibody which could neutralize the EBV DNA
polymerase activity was prepared and found to recognize 55,000- and 49,000-dalton polypeptides. An EA-D
monoclonal antibody, R3 (G. R. Pearson, V. Vorman, B. Chase, T. Sculley, M. Hummel, and E. Kieff, J.
Virol. 47:183-201, 1983), was also able to recognize these same two polypeptides associated with EBV DNA
polymerase activity. It was concluded that EBV EA-D polypeptides, as identified by R3 monoclonal antibody,
are critical components of EBV DNA polymerase.
Epstein-Barr virus (EBV) is a herpesvirus which is closely
associated with some human malignancies, such as Burkitt's
lymphoma and nasopharyngeal carcinoma (NPC). In addi-
tion, it is associated with some human infectious diseases.
One of the critical enzymes responsible for EBV DNA
replication in productively infected cells is EBV-specified
DNA polymerase (DP). With a partially purified preparation
of this enzyme, it was found that DP activity could be
stimulated by salts, such as potassium chloride and ammo-
nium sulfate, and inhibited by phosphonoformate (1, 2, 5, 11,
17). Furthermore, the substrate specificity of EBV DP is
different from those of human cellular DPs. In the course of
EBV DP purification from phorbol-12-myristate-13-acetate-
treated P3HR-1 cells, an EBV DP-specific stimulatory pro-
tein with a molecular mass of 45,000 daltons was found, and
an antibody against this stimulatory protein could be dem-
onstrated in serum from patients with NPC. The stimulatory
protein did not alter the Km value of the substrate but did
increase the Vmax value of highly purified EBV DP (1). It was
reported that the major protein component in EBV DP from
n-butyrate-treated P3HR-1 cells is a polypeptide having a
molecular weight of 110,000 (7). This is quite different from
the DP induced by herpes simplex virus, which is composed
of two polypeptides with different molecular weights (14).
Several viral proteins are synthesized during the early
period of EBV replication. Based on resistance to methanol
and cellular localization by immunofluorescence assay, two
early antigens, diffused (EA-D) and restricted, were classi-
fied (6). Monoclonal antibodies (R3) against EA-D were
prepared and found to recognize two virus-induced polypep-
tides with molecular weights of 50,000 and 52,000 (12). The
gene responsible for the synthesis of these two polypeptides
was found to be in the BamHI M fragment of the EBV
genome (18). The function of EA-D polypeptides is presently
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unclear. In this study, we suggested that EBV DP has EA-D
polypeptides as its components.
EBV DP is induced by chemical agents not only in virus
producer P3HR-1 cells, but also in latently infected cells
such as Raji cells (2, 7, 8, 10, 11, 17). The general properties
of EBV DP induced in these cell lines by different conditions
are similar. High titers of antibody against EA-D were found
in NPC serum (6, 12), and recently, antibodies which could
neutralize the activity of a relatively crude preparation of
EBV DP were also found (17). The neutralizing activity
could be the result of antibody interaction with either EBV
DP-specific stimulatory protein or other components of EBV
DP. To induce enough activity to further characterize EBV
DP, we chose Raji cells treated with phorbol-12,13-dibutyr-
ate and n-butyrate as the source of the enzyme. Sequential
chromatography on phosphocellulose, DEAE-cellulose,
double-stranded DNA-cellulose, and blue Sepharose col-
umns with salt-gradient elution was employed for purifica-
tion.
All the buffers used in chromatography procedures con-
tained 20% glycerol, 5 mM dithiothreitol, 5 mM EDTA, 1
mM phenylmethylsulfonyl fluoride, and 0.5 ,ug/ml each of
pepstatin and leupeptin; salt concentrations and pH values
are indicated where appropriate. The linear gradients used
for column elution contained 0 to 0.6 M KCI in 50 mM KPO4
buffer, pH 8.0, except for that used for DEAE-cellulose
chromatography, which contained 50 mM to 0.4 M KPO4,
pH 7.5. Raji cells were cultivated in RPMI 1640 medium
supplemented with 10% fetal calf serum and 100 ,ug of
kanamycin per ml. The chemical inducers were added at
final concentrations of 50 nM for phorbol-12,13-dibutyrate
and 4 mM for n-butyrate. The cells were harvested at 48 h
postinduction, washed twice with cold phosphate-buffered
saline, and suspended in extraction buffer containing 0.3 M
KCI, 40 mM Tris hydrochloride (pH 7.5), 2 mM MgCl2, 5
mM 3-mercaptoethanol, 1 mM phenylmethylsulfonyl fluo-
ride, and 20% glycerol. The cells were then freeze-thawed
three times, and the extract was centrifuged at 12,000 x g for
15 min. The supernatant was passed over a DEAE-cellulose
column that had been preequilibrated with 0.4 M KPO4
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FIG. 1. Purification profiles of EBV DP on phosphocellulose
column (A), DEAE-cellulose column (B), and double-stranded
DNA-cellulose column (C). Immunodot results are shown in the
insets; the numbers represent fractions.
buffer, pH 7.5, to remove nucleic acids. The EBV DP was
then purified in four chromatography steps (Fig. 1 and 2A),
and EBV DP and DNase activities were monitored. The
assay mixture for EBV DP was composed of 50 mM Tris
hydrochloride (pH 8.0), 4 mM MgCl,, 0.6 mM dithiothreitol,






















FIG. 2. (A) Purification profile of EBV DP on blue Sepharose
column. Immunodot result is shown in the inset; the numbers
represent fractions. (B) Silver stain using fractions 31 to 36 after blue
Sepharose column. Molecular weight of proteins (in thousands [K])
is indicated. (C) Western blot immunostain. Primary antibodies used
were pooled NPC sera (lane a), monoclonal antibody R3 (lane b),
and MCAb 49-6 (lane c).
TABLE 1. Purification of EBV DP
Purification Total Recovery Sp act Purification
step activity (U) (%) (U/mg) (fold)
Crude extract 60,107 100 402 1
Phosphocellulose 35,431 60 4,724 11.8
DEAE-cellulose 2,035 3.4 4,915 12.2
Double-stranded 1,038 1.7 13,308 33.5
DNA-cellulose
Blue Sepharose 642 1.1 89,167 223
dATP, dCTP, and dGTP, 5 FjM [3H]TTP, and 100 mM
(NH4)2SO4 in a total volume of 100 ,ul. One unit of EBV DP
activity is the same as that defined previously (1). The EBV
DNase assay was essentially the same as that reported
previously (16).
EBV DP was virtually separated from EBV DNase activ-
ity by the first chromatographic step (phosphocellulose). The
majority of the EBV DP activity was lost after the DEAE-
cellulose column step. This could be explained by the
dissociation of EBV DP-specific stimulatory protein from
EBV DP at this stage of the purification. When the stimula-
tory protein was added back to the DP activity peak from
DEAE-cellulose, DP activity increased more than sevenfold
(data not shown). EBV DP was purified more than 200-fold
by the four chromatographic steps (Table 1). If the sevenfold
stimulation of EBV DP by the stimulatory protein is taken
into account, then the EBV DP was purified more than
1,000-fold by this entire purification protocol.
To check the purity of the EBV DP, fractions 31 to 36 from
the final step in the purification were electrophoresed on a
sodium dodecyl sulfate-7.5% polyacrylamide gel. Silver
staining showed that four polypeptides having molecular
weights of 110,000, 100,000, 55,000, and 49,000 were asso-
ciated with the DP activity peak (Fig. 2B). The nature of
68,000-, 64,000-, and 24,000-dalton polypeptides is unclear at
present and is under further investigation. Pooled sera from
patients with NPC recognized all four polypeptides (Fig. 2C,
lane a). A monoclonal antibody, designated MCAb 49-6,
which could neutralize EBV DP activity, was prepared in
this laboratory with a partially purified enzyme preparation
as an antigen. This antibody could recognize two polypep-
tides with molecular masses of 55,000 and 49,000 daltons in
peak DP fractions from the blue Sepharose column (Fig. 2C,
lane c). Since these two polypeptides have a molecular mass
similar to that reported previously for EA-D (9, 13), this
observation raised the possibility that the two polypeptides
detected by MCAb 49-6 were EA-D. A monoclonal antibody
(R3) against EA-D was examined for its ability to recognize
those two polypeptides in our preparation. This antibody
recognized the same two polypeptides that MCAb 49-6 did
(Fig. 2C, lane b). To examine whether EBV DP was always
associated with EA-D, dot blots of fractions throughout the
purification were immunostained with monoclonal antibody
R3 (Fig. 1 and 2A). The results showed that EBV DP could
not be separated from EA-D on phosphocellulose, double-
stranded DNA-cellulose, and blue Sepharose columns, and
the intensity of staining correlated with the peaks of EBV DP
activity. At the DEAE-cellulose step, a component(s) of
EA-D may be partially separated; however, this was not
investigated further. The same pattern was obtained with
MCAb 49-6 (data not shown).
The MCAb 49-6 was further purified on a protein A-Seph-
arose column (4) and was determined to be of the immuno-
globulin G 2a subtype, based on the elution condition from
















i 3 5 (pi)
MCAb
FIG. 3. (A) Neutralization with MCAb 49-6 on EBV DP (A),
herpes simplex virus type 2 DP (0), and human DP a (O). (B)
Neutralization with MCAb 49-6 (A), R3 (0), and monoclonal
antibody against EBV early antigen restricted component (O) on
EBV DP purified on blue Sepharose column. The enzyme activity
was 0.3 to 0.5 U for each assay.
activity were examined. EBV, herpes simplex virus type 2,
and human ot DPs were incubated with MCAb 49-6 at room
temperature for 20 min, and then their respective reaction
mixtures were added to initiate the enzyme reaction at 37°C
for 20 min. The results are depicted in Fig. 3. MCAb 49-6
strongly neutralized EBV DP activity but had no effect on
herpes simplex virus type 2 and human DPs (Fig. 3A). The
monoclonal antibody (R3) against EA-D also neutralized
EBV DP activity. The monoclonal antibody against another
early antigen, early antigen restricted component, did not
affect the enzyme activity (Fig. 3B). EBV DP derived from
P3HR-1 cells, an EBV producer, was also neutralized by the
R3 and MCAb 49-6 monoclonal antibodies (data not shown).
In this study, EBV-specified DP was purified from Raji
cells induced with phorbol-12,13-dibutyrate and n-butyrate,
and four polypeptides having molecular masses of 110,000,
100,000, 55,000, and 49,000 daltons coincided with EBV DP
activity and were recognized by NPC serum. Thus, the
neutralizing activity of NPC serum could be the result of the
interaction with these polypeptides, in addition to EBV
DP-specific stimulatory protein. The polypeptide of 110,000
daltons appears to be a component of EBV DP, which is in
agreement with results of other investigators (7). However,
the 110,000-dalton polypeptide is insufficient for EBV DP
activity, according to the results presented here. The poly-
peptides with molecular masses of 55,000 and 49,000 daltons
are essential to EBV DP activity and appear to be compo-
nents of EA-D (9). It is suggested that EA-D is a critical
component of EBV DP activity and may therefore function
in EBV DNA replication. The observations made by others
(3, 11, 15) also substantiate this notion.
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